ARTICLE | Product Development
Master protocols should not be a one-off phenomenon confined to COVID-19
COVID-19 gives a master lesson in platform trials
September 10, 2020 12:30 AM UTC
This is the fourth article in BioCentury’s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert its COVID response to a new era of efficient drug development.
COVID-19 has shown how a mammoth network of platform trials would have system-wide benefits for biotech and patients...